Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Coherus BioSciences, Inc. (NASDAQ:CHRS), a commercial-stage biopharmaceutical company with a market capitalization of approximately $149 million, has undergone a significant transformation in recent ...

ALX Oncology (NASDAQ:ALXO) stock fell 16% Thursday after the company reported updated data from a Phase 2 study called ASPEN-06 for its drug candidate evorpacept. ALX said the data showed evorpacept ...

David M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care in Cincinnati, Ohio, has transformed ...

Rising diagnoses of certain cancers in people under 50 predate the rollout of COVID-19 vaccines by decades, undermining ...

Predictive Oncology Inc (POAI) stock saw a modest uptick, ending the day at $1.48 which represents a slight increase of $0.21 or 16.54% from the prior close of $1.27. The stock opened at $1.58 and ...

Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

The Precision Oncology Showcase is a webinar series sponsored by SOPHiA GENETICS, set to redefine how precision oncology is ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical ...